100 related articles for article (PubMed ID: 25080901)
1. SGI-1776, an imidazo pyridazine compound, inhibits the proliferation of ovarian cancer cells by inactivating Pim-1.
Xie J; Bai J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 39(7):649-57. PubMed ID: 25080901
[TBL] [Abstract][Full Text] [Related]
2. Biochemical changes of salivary gland adenoid cystic carcinoma cells induced by SGI-1776.
Hou X; Yu Y; Feng J; Wang J; Zheng C; Ling Z; Ge M; Zhu X
Exp Cell Res; 2017 Mar; 352(2):403-411. PubMed ID: 28228352
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.
Chen LS; Redkar S; Taverna P; Cortes JE; Gandhi V
Blood; 2011 Jul; 118(3):693-702. PubMed ID: 21628411
[TBL] [Abstract][Full Text] [Related]
4. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells.
Chen LS; Redkar S; Bearss D; Wierda WG; Gandhi V
Blood; 2009 Nov; 114(19):4150-7. PubMed ID: 19734450
[TBL] [Abstract][Full Text] [Related]
5. Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma.
Cervantes-Gomez F; Chen LS; Orlowski RZ; Gandhi V
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S317-29. PubMed ID: 23988451
[TBL] [Abstract][Full Text] [Related]
6. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
[TBL] [Abstract][Full Text] [Related]
7. The novel anti-adipogenic effect and mechanisms of action of SGI-1776, a Pim-specific inhibitor, in 3T3-L1 adipocytes.
Park YK; Hong VS; Lee TY; Lee J; Choi JS; Park DS; Park GY; Jang BC
Int J Mol Med; 2016 Jan; 37(1):157-64. PubMed ID: 26719859
[TBL] [Abstract][Full Text] [Related]
8. Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.
Batra V; Maris JM; Kang MH; Reynolds CP; Houghton PJ; Alexander D; Kolb EA; Gorlick R; Keir ST; Carol H; Lock R; Billups CA; Smith MA
Pediatr Blood Cancer; 2012 Oct; 59(4):749-52. PubMed ID: 22052829
[TBL] [Abstract][Full Text] [Related]
9. PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells.
Siu A; Virtanen C; Jongstra J
Oncotarget; 2011 Dec; 2(12):1134-44. PubMed ID: 22193779
[TBL] [Abstract][Full Text] [Related]
10. PIM kinases as therapeutic targets against advanced melanoma.
Shannan B; Watters A; Chen Q; Mollin S; Dörr M; Meggers E; Xu X; Gimotty PA; Perego M; Li L; Benci J; Krepler C; Brafford P; Zhang J; Wei Z; Zhang G; Liu Q; Yin X; Nathanson KL; Herlyn M; Vultur A
Oncotarget; 2016 Aug; 7(34):54897-54912. PubMed ID: 27448973
[TBL] [Abstract][Full Text] [Related]
11. Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.
Mahalingam D; Espitia CM; Medina EC; Esquivel JA; Kelly KR; Bearss D; Choy G; Taverna P; Carew JS; Giles FJ; Nawrocki ST
Br J Cancer; 2011 Nov; 105(10):1563-73. PubMed ID: 22015557
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis induced by 7-difluoromethoxyl-5,4'-di-n-octyl genistein via the inactivation of FoxM1 in ovarian cancer cells.
Ning Y; Li Q; Xiang H; Liu F; Cao J
Oncol Rep; 2012 Jun; 27(6):1857-64. PubMed ID: 22447287
[TBL] [Abstract][Full Text] [Related]
13. PIM kinases 1, 2 and 3 in intracellular LIF signaling, proliferation and apoptosis in trophoblastic cells.
Mary Photini S; Chaiwangyen W; Weber M; Al-Kawlani B; Favaro RR; Jeschke U; Schleussner E; Morales-Prieto DM; Markert UR
Exp Cell Res; 2017 Oct; 359(1):275-283. PubMed ID: 28729093
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes.
Mumenthaler SM; Ng PY; Hodge A; Bearss D; Berk G; Kanekal S; Redkar S; Taverna P; Agus DB; Jain A
Mol Cancer Ther; 2009 Oct; 8(10):2882-93. PubMed ID: 19825806
[TBL] [Abstract][Full Text] [Related]
15. Role of oncogene PIM-1 in the development and progression of papillary thyroid carcinoma: Involvement of oxidative stress.
Wen QL; Yi HQ; Yang K; Yin CT; Yin WJ; Xiang FY; Bao M; Shuai J; Song YW; Ge MH; Zhu X
Mol Cell Endocrinol; 2021 Mar; 523():111144. PubMed ID: 33383107
[TBL] [Abstract][Full Text] [Related]
16. Chikusetsusaponin IVa methyl ester induces G1 cell cycle arrest, triggers apoptosis and inhibits migration and invasion in ovarian cancer cells.
Chen X; Wu QS; Meng FC; Tang ZH; Chen X; Lin LG; Chen P; Qiang WA; Wang YT; Zhang QW; Lu JJ
Phytomedicine; 2016 Dec; 23(13):1555-1565. PubMed ID: 27823619
[TBL] [Abstract][Full Text] [Related]
17. Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition.
Iqbal A; Eckerdt F; Bell J; Nakano I; Giles FJ; Cheng SY; Lulla RR; Goldman S; Platanias LC
Oncotarget; 2016 May; 7(22):33192-201. PubMed ID: 27120806
[TBL] [Abstract][Full Text] [Related]
18. A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.
Foulks JM; Carpenter KJ; Luo B; Xu Y; Senina A; Nix R; Chan A; Clifford A; Wilkes M; Vollmer D; Brenning B; Merx S; Lai S; McCullar MV; Ho KK; Albertson DJ; Call LT; Bearss JJ; Tripp S; Liu T; Stephens BJ; Mollard A; Warner SL; Bearss DJ; Kanner SB
Neoplasia; 2014 May; 16(5):403-12. PubMed ID: 24953177
[TBL] [Abstract][Full Text] [Related]
19. PIM kinase inhibitors downregulate STAT3(Tyr705) phosphorylation.
Chang M; Kanwar N; Feng E; Siu A; Liu X; Ma D; Jongstra J
Mol Cancer Ther; 2010 Sep; 9(9):2478-87. PubMed ID: 20667852
[TBL] [Abstract][Full Text] [Related]
20. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels.
Morishita D; Katayama R; Sekimizu K; Tsuruo T; Fujita N
Cancer Res; 2008 Jul; 68(13):5076-85. PubMed ID: 18593906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
